SCHEMBL3392440

SCHEMBL3392440

Cc1cccc2ccc(C(=O)O)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2D Q9UNK4 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2A6 P11509 2/20 0.55
PTPN1 P18031 1/20 0.51
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM2B Q8NHM5 4/20 0.48
GRIN2D O15399 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2C Q14957 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA6 P23280 1/20 0.47
CA9 Q16790 1/20 0.47
SLC22A12 Q96S37 1/20 0.46
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6913198 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6915628 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6915625 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6916112 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6913196 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6916107 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6914715 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6915863 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6909998 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1
SCHEMBL6916929 0.98 PLA2G2D (0.54) PLA2G2DCYP1A2CYP2A6PTPN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4748227-A Process for preparing poly(aryl ether)ketones using a sodium carbonate/organic acid salt catalyst AMOCO CORPORATION (US) 1988-05-31 US claimed
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
EP-3230339-B1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL TORAY INDUSTRIES (JP) 2022-03-23 EP disclosed
CN-107001594-B Composition epoxy resin, prepreg, the manufacturing method of fiber reinforced plastic materials and fiber reinforced plastic materials 东丽株式会社 2019-07-23 CN disclosed
US-20170362376-A1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL TORAY INDUSTRIES, INC. (JP) 2017-12-21 US disclosed
EP-3230339-A1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL Toray Industries, Inc. (JP) 2017-10-18 EP disclosed
CN-107001594-A Composition epoxy resin, prepreg, the manufacture method of fiber reinforced plastic materials and fiber reinforced plastic materials 东丽株式会社 2017-08-01 CN disclosed
WO-2016087935-A1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL TORAY INDUSTRIES, INC. (JP) 2016-06-09 WO disclosed
CN-102725273-B Inclusion compound and manufacture method thereof NIPPON SODA CO.,LTD. (JP) 2016-02-17 CN disclosed
US-20120041036-A1 SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) ASTELLAS PHARMA INC. (JP) 2012-02-16 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
CN-101802049-A Epoxy resin composition for semiconductor encapsulation containing inclusion complex NIPPON SODA CO 2010-08-11 CN disclosed
US-20100179250-A1 INCLUSION COMPLEX CONTAINING EPOXY RESIN COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION NIPPON SODA CO., LTD. (JP) 2010-07-15 US disclosed
EP-2192139-A1 INCLUSION COMPLEX CONTAINING EPOXY RESIN COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION Nippon Soda Co., Ltd. (JP) 2010-06-02 EP disclosed
US-20060128823-A1 Radiation curable inkjet recording ink, and method of producing planographic printing plate using same, and ink composition, inkjet recording method, printed material, method of producing a planographic printing plate, and planographic printing plate FUJI PHOTO FILM CO., LTD. 2006-06-15 US disclosed
EP-1657286-A2 Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye FUJI PHOTO FILM CO., LTD. (JP) 2006-05-17 EP disclosed
CN-1022755-C Process for preparation of N-imidazolyl-and N-imidazolyl methyl-derivatives of substituted bicyclic compounds ERBA CARLO SPA (IT) 1993-11-17 CN disclosed
CN-1041587-A The preparation method of the TMSIM N imidazole base of substituted bicyclic compounds and TMSIM N imidazole ylmethyl derivative ERBA CARLO SPA (IT) 1990-04-25 CN disclosed
US-4224225-A PHOTOPOLYMERIZATION INITIATOR FUJI PHOTO FILM CO., LTD. (JP) 1980-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A PLA2G2D 841/4885CYP1A2 605/4885CYP2A6 1209/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 PLA2G2D 3306/4885CYP1A2 4125/4885CYP2A6 4620/4885
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB PLA2G2D 3518/4885CYP1A2 1279/4885CYP2A6 617/4885
US-20120041036-A1 SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) HTR5A, HTR2A, HTR1A PLA2G2D 1120/4885CYP1A2 382/4885CYP2A6 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.